Merck KGaA
Also known as: an affiliate of Merck KGaA, Darmstadt, Germany | Consultant Medical Oncologist | EMD Serono, a business of Merck KGaA, Darmstadt, Germany | EMD Serono, an affiliate of Merck KGaA Darmstadt, Germany | EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany | EMD Serono, an affiliate of MerckKGaA, Darmstadt, Germany | EMD Serono, Senior Medical Director, Rheumatology | Merck A.E. Hellas, an affiliate of Merck KGaA, Darmstadt, Germany | Merck Gesellschaft mbH, Zimbagasse 5, 1147 Vienna, Austria | Merck Healthcare KGaA | Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA, Darmstadt, Germany Merck | Merck KGaA | MERCK KGAA | Merck KGaA, Darmstadt | Merck KGaA, Darmstadt, Germany | Merck KGaA/EMD Serono | Merck Ltd., Korea, an affiliate of Merck KGaA, Darmstadt, Germany | Merck Medication Familiale | Merck Pharmaceutical Manufacturing (Jiangsu) Co., Ltd., an affiliate of Merck KGaA, Darmstadt, Germany | Merck Romania SRL, an affiliate of Merck KGaA, Darmstadt, Germany | Merck S.A de C.V, Mexiko, an affiliate of Merck KGaA, Darmstadt, Germany | Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd., an Affiliate of Merck KGaA, Darmstadt, Germany | Merck Serono (Beijing), Pharmaceutical R&D Co., Ltd., an Affiliate of Merck KGaA Darmstadt, Germany | Merck Serono Co. Ltd. an affiliate of Merck KGaA, Darmstadt, Germany | Merck Serono Co., Ltd., Beijing, an affiliate of Merck KGaA, Darmstadt, Germany | Merck Serono Co., Ltd., Beijing, China | Merck Serono Co., Ltd. Japan, an business of Merck KGaA, Darmstadt, Germany | Merck Serono Co., Ltd., Tokyo, an affiliate of Merck KGaA, Darmstadt, Germany | Merck Serono GmbH, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Merck Serono Middle East FZ-LLC, United Arab Emirates, an affiliate of Merck KGaA, Darmstadt, Germany | PT Merck Tbk, Indonesia, and affiliate of Merck KGaA, Darmstadt, Germany
Highest phase reached
Phase 4
First clinical trial
Feb 29, 1992First marketed drug
Jun 1, 1827First NDA
Jun 1, 1827Last known activity
Jan 2, 2026
Timeline
1660s
- Jan 1, 1668
Merck KGaA— Founded
1820s
- Jun 1, 1827
morphine— NDA Organization
1990s
- Jan 1, 1991
Lipha— Acquired
- Dec 17, 1998
Lexigen Pharmaceuticals— Acquired
2000s
- Jan 1, 2003
ProteoPlex— Acquired
- Jun 16, 2005
levothyroxine— Marketing Organization
- Jan 1, 2006
Merck Serono— Acquired By
- Jan 1, 2006
Serono— Acquired
2010s
- Jan 1, 2010
Millipore— Acquired
- Jan 1, 2013
AZ Electronics— Acquired
- Jan 1, 2014
Sigma-Aldrich— Acquired
- Jan 1, 2015
Qlight Nanotech— Acquired
2020s
- Jan 8, 2021
Amptec— Acquired
Drugs by trial phase (200 distinct, 403 trials)
Phase 4 (21 own, 4 via acquisition)
Phase 3 (38 own, 5 via acquisition)
Phase 2 (73 own, 1 via acquisition)
Phase 1 (52 own, 1 via acquisition)
Other trials (5 own, 0 via acquisition)
Indications
Approved for
Studied for
- Adenocarcinoma
- Alzheimer Disease
- Aneurysm
- Angina Pectoris
- Angina, Stable
- Anovulation
- Aortic Aneurysm
- Aortic Aneurysm, Abdominal
- Arthritis
- Arthritis, Rheumatoid
- Biliary Tract Neoplasms
- Breast Neoplasms
- Carcinoma
- Carcinoma, Adenoid Cystic
- Carcinoma, Hepatocellular
- Carcinoma, Merkel Cell
- Carcinoma, Neuroendocrine
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Small Cell
- Carcinoma, Squamous Cell
- Cholangiocarcinoma
- Colonic Neoplasms
- Colorectal Neoplasms
- Complex Regional Pain Syndromes
- Coronary Artery Disease
- Coronary Disease
- Coronavirus Infections
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diabetic Neuropathies
- Dwarfism
- Dwarfism, Pituitary
- Endocrine System Diseases
- Esophageal Neoplasms
- Essential Hypertension
- Fallopian Tube Neoplasms
- Fetal Growth Retardation
- Fibromyalgia
- Gallbladder Neoplasms
- Gastrointestinal Neoplasms
- Gestational Trophoblastic Disease
- Glioblastoma
- Glioma
- Glomerulonephritis, IGA
- Gonadal Disorders
- Gonadal Dysgenesis
- Head and Neck Neoplasms
- Heart Diseases
- Heart Failure
- Heart Failure, Systolic
- Hemangiosarcoma
- Hematologic Neoplasms
- Hypertension
- Hypogonadism
- Infertility
- Kidney Diseases
- Leiomyosarcoma
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Limb Deformities, Congenital
- Liver Diseases
- Liver Neoplasms
- Lordosis
- Lung Diseases
- Lung Diseases, Interstitial
- Lung Neoplasms
- Lupus Erythematosus, Cutaneous
- Lupus Erythematosus, Systemic
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Extranodal NK-T-Cell
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Malaria
- Melanoma
- Microsatellite Instability
- Multiple Myeloma
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Myocardial Ischemia
- Myofascial Pain Syndromes
- Nasopharyngeal Carcinoma
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Plasma Cell
- Neoplasms, Squamous Cell
- Neoplasms, Unknown Primary
- Neuralgia
- Neuritis
- Neuroendocrine Tumors
- Optic Neuritis
- Oropharyngeal Neoplasms
- Osteoarthritis
Marketed drugs (3)
Subsidiaries (9 direct, 43 total across the full acquisition tree)
- Amptec
- AZ Electronics
- Lexigen Pharmaceuticals
- Lipha
- Millipore
- ProteoPlex
- Qlight Nanotech
- Serono
- Sigma-Aldrich
- Advanced Separation Technologies L2
- Aldrich L2
- Amicon Separation Science L2
- Beijing Superior Chemicals and Instruments Co L2
- BioAnaLab L2
- Bioprocessing Limited L2
- BioReliance L2
- Degussa L2
- Epichem Group L2
- Genset L2
- Guava Technologies L2
- Interpharm L2
- Iropharm L2
- Isotec L2
- JRH Biosciences L2
- Microsafe Laboratories BV L2
- Molecular Medicine BioServices L2
- Newport Bio Systems L2
- Novaseptic AB L2
- Pharmorphix L2
- Serologicals Corporation L2
- Sigma Chemical Company L2
- Sorebio L2
- Tylan General L2
- Ultrafine L2
- Waters Associates L2
- Asta Medica L3
- Asta Werke L3
- Bioscot, Ltd. L3
- Chemisch-Pharmazeutische AG L3
- Muro Pharmaceuticals L3
- Proligo L3
- Sarget S.A. L3
- Pharmacy Barthe L4
Recent trials (50)
- NCT07311603CollaboratorPhase 1Jan 2, 2026
- NCT07311603OfficialPhase 1Jan 2, 2026
- NCT07311603Lead sponsorPhase 1Jan 2, 2026
- NCT07269327OfficialPhase 1Nov 24, 2025
- NCT07269327CollaboratorPhase 1Nov 24, 2025
- NCT07269327Lead sponsorPhase 1Nov 24, 2025
- NCT07110038CollaboratorPhase 2Oct 31, 2025
- NCT07166601CollaboratorPhase 1Oct 10, 2025
- NCT07097259CollaboratorPhase 1Jul 21, 2025
- NCT06710132CollaboratorPhase 1/Phase 2Feb 15, 2025
- NCT06710132CollaboratorPhase 1/Phase 2Feb 15, 2025
- NCT06710132OfficialPhase 1/Phase 2Feb 15, 2025
- NCT06719973CollaboratorPhase 1Jan 6, 2025
- NCT06806046Lead sponsorPhase 1Dec 20, 2024
- NCT06806046CollaboratorPhase 1Dec 20, 2024
Details
- Founded
- Darmstadt, DE Jan 1, 1668
- First NDA
- Jun 1, 1827
- Last known activity
- Jan 2, 2026
Designations held
- Priority review